Matthew Gall - Net Worth and Insider Trading
Matthew Gall Net Worth
The estimated net worth of Matthew Gall is at least $558,764 dollars as of 2024-11-29. Matthew Gall is the CFO of ITeos Therapeutics Inc and owns about 65,429 shares of ITeos Therapeutics Inc (ITOS) stock worth over $558,764. Details can be seen in Matthew Gall's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Matthew Gall has not made any transactions after 2024-11-19 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Matthew Gall
Matthew Gall Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Matthew Gall owns 1 companies in total, including ITeos Therapeutics Inc (ITOS) .
Click here to see the complete history of Matthew Gall’s form 4 insider trades.
Insider Ownership Summary of Matthew Gall
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
ITOS | ITeos Therapeutics Inc | 2024-11-19 | Chief Financial Officer |
Matthew Gall Latest Holdings Summary
Matthew Gall currently owns a total of 1 stock. Matthew Gall owns 65,429 shares of ITeos Therapeutics Inc (ITOS) as of November 19, 2024, with a value of $558,764.
Latest Holdings of Matthew Gall
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
ITOS | ITeos Therapeutics Inc | 2024-11-19 | 65,429 | 8.54 | 558,764 |
Holding Weightings of Matthew Gall
Matthew Gall Form 4 Trading Tracker
According to the SEC Form 4 filings, Matthew Gall has made a total of 4 transactions in ITeos Therapeutics Inc (ITOS) over the past 5 years, including 3 buys and 1 sells. The most-recent trade in ITeos Therapeutics Inc is the acquisition of 5,000 shares on November 19, 2024, which cost Matthew Gall around $38,650.
Insider Trading History of Matthew Gall
- 1
Matthew Gall Trading Performance
GuruFocus tracks the stock performance after each of Matthew Gall's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Matthew Gall is 21.22%. GuruFocus also compares Matthew Gall's trading performance to market benchmark return within the same time period. The performance of stocks bought by Matthew Gall within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Matthew Gall's insider trading performs compared to the benchmark.
Matthew Gall Ownership Network
Matthew Gall Owned Company Details
What does ITeos Therapeutics Inc do?
Who are the key executives at ITeos Therapeutics Inc?
Matthew Gall is the Chief Financial Officer of ITeos Therapeutics Inc. Other key executives at ITeos Therapeutics Inc include other: See remarks Aaron I. Davis , other: See remarks Boxer Capital, Llc , and other: See remarks Boxer Asset Management Inc. .
ITeos Therapeutics Inc (ITOS) Insider Trades Summary
Over the past 18 months, Matthew Gall made 2 insider transaction in ITeos Therapeutics Inc (ITOS) with a net purchase of 10,000. Other recent insider transactions involving ITeos Therapeutics Inc (ITOS) include a net sale of 350,000 shares made by Boxer Capital, Llc ,
In summary, during the past 3 months, insiders sold 0 shares of ITeos Therapeutics Inc (ITOS) in total and bought 5,000 shares, with a net purchase of 5,000 shares. During the past 18 months, 350,000 shares of ITeos Therapeutics Inc (ITOS) were sold and 10,000 shares were bought by its insiders, resulting in a net sale of 340,000 shares.
ITeos Therapeutics Inc (ITOS)'s detailed insider trading history can be found in Insider Trading Tracker table.
ITeos Therapeutics Inc Insider Transactions
Matthew Gall Mailing Address
Above is the net worth, insider trading, and ownership report for Matthew Gall. You might contact Matthew Gall via mailing address: C/o Iteos Therapeutics, Inc., 139 Main Street, Cambridge Ma 02142.